Table 3.
Drug likeliness properties of the Apigenin analogues by swissAdme, osiris and Molinspiration
| Drug likeness properties |
Boceprevir | Apigenin | Apigenin 7-glucoside-4’-p-coumarate | Apigenin 7-glucoside-4’-trans-caffeate | Apigenin 7-O-beta-D-glucoside (Cosmosiin) |
|---|---|---|---|---|---|
|
Bioavaibility and drug-scorea |
|||||
| Molecular weight g/mol | 519.68 | 270.24 | 578.52 | 594.52 | 432.38 |
| cLogP | 1.38 | 2.34 | 2.11 | 1.76 | 0.35 |
| Solubility | −4.02 | −2.86 | −4.58 | −4.29 | −2.74 |
| TPSA | 150.7 | 86.99 | 192.4 | 212.6 | 166.1 |
| Druglikness | −8.76 | 1.21 | −3.55 | −2.7 | −2.29 |
| Drug-score | 0.11 | 0.47 | 0.12 | 0.13 | 0.44 |
| Druglikness b | |||||
| GPCR ligand | 0.50 | −0.07 | −0.04 | −0.09 | 0.1 |
| Ion channel modulator | 0.04 | −0.09 | −0.49 | −0.55 | −0.01 |
| Kinase inhibitor | −0.03 | 0.18 | −0.12 | −0.21 | 0.14 |
| Nuclear receptor ligand | 0.07 | 0.34 | 0.07 | −0.02 | 0.31 |
| Protease inhibitor | 1.41 | −0.25 | −0.04 | −0.06 | 0.02 |
| Enzyme inhibitor | 0.31 | 0.26 | 0.14 | 0.07 | 0.43 |
| Pharmacokinetics c | |||||
| GI absorption | Low | High | Low | Low | Low |
| BBB permeant | No | No | No | No | No |
| P-gp substrate | Yes | No | No | No | Yes |
| CYP1A2 inhibitor | No | Yes | No | No | No |
| CYP2C19 inhibitor | No | No | No | No | No |
| CYP2C9 inhibitor | No | No | Yes | Yes | No |
| CYP2D6 inhibitor | No | Yes | No | No | No |
| CYP3A4 inhibitor | Yes | Yes | No | No | No |
GI: Gastrointestinal absorption; BBB: blood brain barrier; P-gp: Permeability Glycoprotein; CYP: Cytochrome P450; a = Osiris; b = Molinspiration; c = SwissAdme.